reMYND
Remynd is a biotech company dedicated to developing innovative treatments for neurodegenerative diseases such as Alzheimer’s and Huntington’s disease. They focus on creating first-in-class oral treatments that aim to restore neuronal function and modify disease progression, with a strong emphasis on scientific excellence and strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
reMYND
Gaston Geenslaan 1, BE-3001 Leuven (Heverlee)
Patents
Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
US-12178805-B2
View DetailsCompounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11939324-B2
View DetailsCompounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11548881-B2
View DetailsIndole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
US-10117850-B2
View DetailsPiperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease
US-9808456-B2
View Details
Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
US-12178805-B2
View DetailsCompounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11939324-B2
View DetailsCompounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11548881-B2
View DetailsIndole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
US-10117850-B2
View DetailsPiperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease
US-9808456-B2
View DetailsProducts
Optimized septin-modulator clinical candidate (Alzheimer’s) — oral small molecule
A second-generation orally available small-molecule septin modulator designed to restore neuronal calcium homeostasis and synaptic function; undergoing Phase 1 clinical evaluation for safety, tolerability and pharmacokinetics.
First-generation septin-modulator investigational candidate (Phase 2a study)
An earlier-generation small-molecule septin modulator that produced symptomatic and biomarker improvements in a small randomized, placebo-controlled Phase 2a study but was limited by off-target effects that curtailed the therapeutic window.
Huntington’s disease lead compound — oral CNS-permeable small molecule
Preclinical lead compound developed to neutralize neurotoxic effects of mutant huntingtin in Huntington’s disease models; demonstrated restoration of cortico-striatal transmission, improved spiny projection neuron survival, and functional motor and neuropsychiatric improvements in mouse models.
Discovery program targeting mitochondrial dysfunction (ALS)
Early-stage discovery research addressing mitochondrial dysfunction as a contributing mechanism in amyotrophic lateral sclerosis, aimed at identifying therapeutic candidates.
Optimized septin-modulator clinical candidate (Alzheimer’s) — oral small molecule
A second-generation orally available small-molecule septin modulator designed to restore neuronal calcium homeostasis and synaptic function; undergoing Phase 1 clinical evaluation for safety, tolerability and pharmacokinetics.
First-generation septin-modulator investigational candidate (Phase 2a study)
An earlier-generation small-molecule septin modulator that produced symptomatic and biomarker improvements in a small randomized, placebo-controlled Phase 2a study but was limited by off-target effects that curtailed the therapeutic window.
Huntington’s disease lead compound — oral CNS-permeable small molecule
Preclinical lead compound developed to neutralize neurotoxic effects of mutant huntingtin in Huntington’s disease models; demonstrated restoration of cortico-striatal transmission, improved spiny projection neuron survival, and functional motor and neuropsychiatric improvements in mouse models.
Discovery program targeting mitochondrial dysfunction (ALS)
Early-stage discovery research addressing mitochondrial dysfunction as a contributing mechanism in amyotrophic lateral sclerosis, aimed at identifying therapeutic candidates.
Services
Preclinical contract research services to assess experimental Alzheimer’s and other neurodegenerative disease treatments using proprietary mouse models and in vivo proof-of-concept studies; services were transitioned to an external specialized provider.
Preclinical contract research services to assess experimental Alzheimer’s and other neurodegenerative disease treatments using proprietary mouse models and in vivo proof-of-concept studies; services were transitioned to an external specialized provider.
Expertise Areas
- Neurodegenerative disease therapeutics
- Small-molecule CNS drug discovery and lead optimization
- Translational in vivo model development
- Early-phase clinical trial management and clinical pharmacology
Key Technologies
- Septin-targeted small-molecule therapeutics
- In vivo mouse models of neurodegeneration
- EEG-based neurophysiological endpoints
- Cerebrospinal fluid biomarker analysis
News & Updates
Belgian Federal Minister Jan Jambon visited remynd's facilities in Leuven, highlighting the company's work in Alzheimer’s research and drug development.
remynd's Phase I study of REM392, a second-generation septin modulator, is progressing with first results expected in early July.
The trial demonstrated significant improvements in memory and neuronal function, though it was terminated early due to off-target effects.
Floor Stam was appointed as CEO and Johan Cardoen as Chairman to advance the company's neurodegeneration programs.
remynd divests its CRO business to focus solely on drug development, with the CRO unit continuing under InnoSer.
A study published in Science reveals compounds that restore calcium balance in neurons by targeting septins, showing neuroprotective effects in Alzheimer’s models.
Belgian Federal Minister Jan Jambon visited remynd's facilities in Leuven, highlighting the company's work in Alzheimer’s research and drug development.
remynd's Phase I study of REM392, a second-generation septin modulator, is progressing with first results expected in early July.
The trial demonstrated significant improvements in memory and neuronal function, though it was terminated early due to off-target effects.
Floor Stam was appointed as CEO and Johan Cardoen as Chairman to advance the company's neurodegeneration programs.
remynd divests its CRO business to focus solely on drug development, with the CRO unit continuing under InnoSer.
A study published in Science reveals compounds that restore calcium balance in neurons by targeting septins, showing neuroprotective effects in Alzheimer’s models.